Search Results
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
action]On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers - NNOX
demand for its products; (ii) in reality, Nano-X's production and manufacturing operations were poorly aligned with demand for the Company's products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (iv) the foregoing significantly increased the likelihood
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lucid Group, Inc . and Certain Officers - LCID
deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company's business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers - AVAV
U.S. Space Force's ongoing efforts to modernize the SCN; (ii) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.On January 20, 2026, AeroVironment announced
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Graphic Packaging Holding Company and Certain Former Officers - GPK
and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing
More news about: Pomerantz LLP
Jun 25, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against ServBanc Holdco, Inc., ServBank, National Association, IF Bancorp, Inc., and its Board of Directors - IROQ
and Special Dividend were misleading insofar as they overstated the likelihood that IF Bancorp shareholders would receive the Special Dividend; and (iii) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable
More news about: Pomerantz LLP
Jun 25, 2026, 09:01 ET Starwood Property Trust Announces Private Offering of Sustainability Bonds
Discussion and Analysis of Financial Condition and Results of Operations"; (ii) defaults by borrowers in paying debt service on outstanding indebtedness; (iii) impairment in the value of real estate property securing the Company's loans or in which the Company invests; (iv) availability of mortgage origination
More news about: Starwood Property Trust, Inc.
Jun 25, 2026, 09:00 ET Fusion's "Twenty Years Away" Just Got Shorter: General Fusion Heats Plasma to 8.4 Million Degrees by Squeezing It
for the company's capital story. General Fusion is currently private, but it has agreed to a business combination with Spring Valley Acquisition Corp. III (Nasdaq: SVAC) ("Spring Valley" or "SVAC"), a special-purpose acquisition company. At closing, Spring Valley would be renamed General Fusion Group
More news about: American News Group
Jun 25, 2026, 09:00 ET GRAIL Completes $110 Million Equity Financing With Samsung Entities
cancers1. The Galleri test is the only MCED test clinically proven through a randomized controlled trial to increase earlier cancer detection (Stage I-III) and reduce Stage IV diagnoses - enabling more patients to have access to potentially curative treatment options2. When added to standard-of-care
More news about: GRAIL, Inc.
Jun 25, 2026, 08:30 ET PITTCO INVESTS IN NSCALE
and Chief Investment Officer Henry Guy.ABOUT PITTCO MANAGEMENT, LLCPittco is the single-family office for Joseph R. "Pitt" Hyde III, founder of AutoZone, and his wife, Barbara. Pittco was established over 30 years ago, and provides investment, accounting, tax, and financial services
More news about: Pittco Management, LLC
Jun 25, 2026, 08:30 ET Visteon Announces $800 Million Share Repurchase Authorization
and the effects of any restructuring or reorganization plans that may be undertaken by our customers, including work stoppages at our customers, and (iii) possible disruptions in the supply of commodities to us or our customers due to financial distress, work stoppages, natural disasters or civil unrest;our
More news about: Visteon Corporation
Jun 25, 2026, 07:50 ET RBLX DEADLINE ALERT: Roblox Corporation (RBLX) Investors with Substantial Losses Have Opportunity to Lead the Roblox Class Action Lawsuit
while continuing to be "enormously bullish" on their tech rollouts as well as claiming to be able to "rely on [their] tremendous organic growth"; and (iii) Roblox relied far too heavily on viral events to drive growth and failed to communicate to investors the potential knock-on impacts of the age verification
More news about: Robbins Geller Rudman & Dowd LLP
Jun 25, 2026, 07:27 ET Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The
More news about: Cardiol Therapeutics Inc.
Jun 25, 2026, 07:10 ET GRAL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence management
More news about: Robbins Geller Rudman & Dowd LLP
Jun 25, 2026, 07:00 ET Nuvation Bio Announces Proposed Convertible Senior Notes Offering
to pay the cost of the capped call transactions described below, (ii) to repay in full all obligations under our senior secured loan agreement, and (iii) for general corporate purposes, which may include working capital, operating expenses, capital expenditures and general and administrative expenses.In
More news about: Nuvation Bio, Inc.
Jun 25, 2026, 06:45 ET CMC Reports Third Quarter of Fiscal 2026 Results
allow: (i) comparison of our earnings to those of our competitors; (ii) a supplemental measure of our underlying business operational performance; and (iii) the assessment of period-to-period performance trends. Management uses non-GAAP financial measures to evaluate financial performance. We have not reconciled
More news about: CMC
Jun 25, 2026, 06:00 ET Hemlo Mining Corp. Announces Increased Mineral Resource Estimate for the Hemlo Gold Mine
from US$1,900/oz in the 2025 Report to US$2,500/oz in the MRE (see Table 4 for sensitivity analysis), (ii) incorporation of additional drilling data, (iii) refinements to the geological model and grade shell orientations, and (iv) addition of the A-Zone.
More news about: Hemlo Mining Corp.
Jun 25, 2026, 05:44 ET CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
will hold exclusive commercialization rights for sugemalimab in Australia and New Zealand across all approved and future indications, including stage III and IV non-small cell lung cancer (NSCLC), gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and extranodal NK/T-cell lymphoma (ENKTL),
More news about: CStone Pharmaceuticals
Jun 25, 2026, 04:30 ET Hyperscale Data Cash, Restricted Cash, Bitcoin, and Silver Assets of Approximately $94.8 Million Represents Approximately 100.42% of Market Capitalization of Common Stock
billion presuming exercise of the two five-year extensions but before any exercise of options for additional power capacity," stated Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We strongly believe that the value we are creating for stockholders, including the recurring monthly revenue
More news about: Hyperscale Data Inc.
Jun 25, 2026, 01:38 ET Beyond Horizons, Forward Together | Kexing Biopharm sluit deelname aan CPHI & PMEC China 2026 af
erythematodes, GB10 voor oogheelkundige aandoeningen en GB20/GB24 voor auto-immuunziekten. Daarnaast trokken de klinische vorderingen van twee fase III-programma's — langwerkende GC en GB05 (interferon-inhalatieoplossing) — veel aandacht.De jarenlange, gestage ontwikkeling van technologieplatforms en
More news about: Kexing Biopharm
Jun 25, 2026, 01:33 ET Além do horizonte, juntos rumo ao futuro | A Kexing Biopharm encerra sua participação na CPHI & PMEC China 2026
oncológica, o GB19/GB26 para o lúpus eritematoso sistêmico, o GB10 para oftalmologia e o GB20/GB24 para doenças autoimunes. Além disso, dois programas em Fase III — o GC de ação prolongada e o GB05 (solução inalatória de interferon) — chamaram bastante atenção devido ao seu progresso clínico.Anos de desenvolvimento
More news about: Kexing Biopharm
Jun 25, 2026, 01:30 ET Más allá de los horizontes, juntos hacia adelante | Kexing Biopharm concluye su participación en CPHI & PMEC China 2026
lupus eritematoso sistémico, el GB10 para oftalmología y el GB20/GB24 para trastornos autoinmunes. Además, los avances clínicos de dos programas de fase III, el GC de acción prolongada y el GB05 (solución de interferón para inhalación), suscitaron un gran interés.Años de desarrollo constante en plataformas
More news about: Kexing Biopharm
Jun 24, 2026, 23:33 ET C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework
programs, including 5 programs at IND or IND-enabling stage, 29 have advanced to investigator-initiated trials (IITs), 7 in clinical supply, and 2 in Phase III clinical trials. For more information, visit www.c-raytherapeutics.com
More news about: C Ray Therapeutics
Jun 24, 2026, 20:30 ET Au-delà des horizons, ensemble pour l'avenir | Kexing Biopharm clôture sa participation aux salons CPHI et PMEC China 2026
disséminé, le GB10 pour l'ophtalmologie et les GB20/GB24 pour les maladies auto-immunes. En outre, les avancées cliniques de deux programmes de phase III — le GC à action prolongée et le GB05 (solution d'interféron pour inhalation) — ont suscité un vif intérêt.Des années de développement constant
More news about: Kexing Biopharm